Valencian hospital begins phase two trials for a new Covid treatment.
THE Hospital Clínico de València has begun important new trials that could lead the way to a new treatment of coronavirus infections through the Haematology Clinical Trials Unit of the Incliva Research Institute. According to a statement released by the Generalitat Valenicana on Sunday, April 18, the treatment works by injecting blood from previously infected donors – specifically, T lymphocytes – into a patient with an active Covid infection.
The donors were identified several months ago during the first stage of the trials at the Hospital La Paz in Madrid, led by Dr Antonio Pérez and the first infusion has already been administered to a patient with coronavirus; the trial is set to last three months, according to Spanish news outlet Levante.
According to Carlos Solano, the head of the Haematology Service of the Hospital Clínico de València, this type of treatment has previously been used in patients with other ailments as a means of accelerating the recovery of immunity.
“Lymphocytes act by identifying and attacking cells infected by the virus, so it cannot divide and spread to other cells,” he said.
The head of the Haematology Clinical Trials Coordinators team, Merche Bou, profusely thanked the people giving up their time to take part in the invaluable research, and said that it “would not have been possible without the invaluable selfless collaboration of donors who, after having suffered from Covid-19 infection, have offered to collaborate in this project, an act for which we are enormously grateful.
“It is a trial in which it has cost a lot to create the process circuit because it presents logistical characteristics and time limits in the processes that require great coordination of the entire team,” he added.
The Euro Weekly News is running a campaign to help reunite Brits in Spain with their family and friends by capping the costs of PCR tests for travel. Please help us urge the UK government to cap the costs here